Ivermectin Versus Albendazole for Chronic Strongyloidiasis

Chronic Strongyloidiasis Clinical Trial

Official title:

Efficacy and Safety of Ivermectin Versus Albendazole for Chronic Strongyloidiasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00765024
• Other study ID #: TM001-2008
• Status: Completed
• Phase: Phase 3
• First received: September 30, 2008
• Last updated: September 3, 2017
• Start date: July 2008
• Est. completion date: April 2010

Study information

• Verified date: September 2017
• Source: Mahidol University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective controlled trial to compare the efficacy and safety of 7-day albendazole, single dose ivermectin, and 2-single dose ivermectin in 72 patients with chronic strongyloidiasis will be conducted at Siriraj Hospital, Bangkok, Thailand.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: April 2010
• Est. primary completion date: April 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Patients with positive strongyloides larva in the stool

Exclusion Criteria:

• Pregnancy

• Lactating women

• Known allergy to any study drug

Related Conditions & MeSH terms

• Chronic Strongyloidiasis
• Strongyloidiasis

Intervention

Drug:
• Ivermectin
single dose of 200 mcg/kg
• ivermectin
two single dose of 200mcg/kg in 2 weeks
• Albendazole
Albendazole 7 days

Locations

Country	Name	City	State
Thailand	Siriraj Hospital	Bangkoknoi	Bangkok

Sponsors (2)

Lead Sponsor	Collaborator
Mahidol University	Atlantic Laboratory Ltd

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	cure rate		1 year
Secondary	safety		1 year